# Clinical Evaluation of Lyral® Dose Response Study

> **NCT02028182** · PHASE2 · COMPLETED · sponsor: **Allerderm** · enrollment: 22 (actual)

## Conditions studied

- Contact Dermatitis

## Interventions

- **BIOLOGICAL:** Lyral®

## Key facts

- **NCT ID:** NCT02028182
- **Lead sponsor:** Allerderm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02028182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02028182, "Clinical Evaluation of Lyral® Dose Response Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02028182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*